Since January 2013, PharmaEngine is collaborating with Guangzhou BeBetter Medicine with the aim of discovering, selecting and developing new chemical entities against predefined targets in oncology. Under the terms of the research agreement, PharmaEngine holds the exclusive rights to manufacture, develop and commercialize new drug candidates in the world with the exception of China, while BeBetter keeps the rights in China (including Hong Kong and Macau).
The partnership with BeBetter represents an important step in developing new drugs through cross-strait cooperation. Combining BeBetter’s expertise in drug research with our expertise in drug development offers multiple synergistic benefits, which will increase overall efficiency and profitability.
The development goal is to develop two novel, patentable chemical entities or analogs with different mechanisms in oncology. BeBetter’s role is to design and synthesize chemical structures, from which suitable candidates are then selected for clinical trials.